Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Venous Thrombosis

  Free Subscription


Articles published in Thromb Haemost

Retrieve available abstracts of 81 articles:
HTML format
Text format



Single Articles


    October 2018
  1. MONREAL M
    Apixaban for Treating Venous Thromboembolism in Real-World Clinical Practice.
    Thromb Haemost. 2018 Oct 17. doi: 10.1055/s-0038-1675241.
    PubMed     Text format    


  2. PASTORI D, Violi F
    Blood Hormones and Venous Thromboembolic Events: Lack of Association or Lack of Standardization?
    Thromb Haemost. 2018 Oct 12. doi: 10.1055/s-0038-1675176.
    PubMed     Text format    


  3. ROETKER NS, MacLehose RF, Hoogeveen RC, Ballantyne CM, et al
    Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study.
    Thromb Haemost. 2018 Oct 8. doi: 10.1055/s-0038-1673613.
    PubMed     Text format     Abstract available


  4. GRANDONE E, Di Micco PP, Villani M, Colaizzo D, et al
    Venous Thromboembolism in Women Undergoing Assisted Reproductive Technologies: Data from the RIETE Registry.
    Thromb Haemost. 2018 Oct 8. doi: 10.1055/s-0038-1673402.
    PubMed     Text format     Abstract available


  5. GRILZ E, Posch F, Konigsbrugge O, Schwarzinger I, et al
    Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer.
    Thromb Haemost. 2018 Oct 8. doi: 10.1055/s-0038-1673401.
    PubMed     Text format     Abstract available


  6. ALBERTSEN IE, Nielsen PB
    Searching for High-Risk Venous Thromboembolism Patients Using Risk Scores: Adding to the Heap or Closing a Gap?
    Thromb Haemost. 2018;118:1686-1687.
    PubMed     Text format    


    August 2018
  7. AGNELLI G, Becattini C, Bauersachs R, Brenner B, et al
    Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study.
    Thromb Haemost. 2018 Aug 13. doi: 10.1055/s-0038-1668523.
    PubMed     Text format     Abstract available


  8. ROETKER NS, Lutsey PL, Zakai NA, Alonso A, et al
    All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.
    Thromb Haemost. 2018 Aug 13. doi: 10.1055/s-0038-1668521.
    PubMed     Text format     Abstract available


  9. PELLAND-MARCOTTE MC, Pole JD, Kulkarni K, Athale U, et al
    Thromboembolism Incidence and Risk Factors in Children with Cancer: A Population-Based Cohort Study.
    Thromb Haemost. 2018 Aug 13. doi: 10.1055/s-0038-1668543.
    PubMed     Text format     Abstract available


  10. KRAAIJPOEL N, Di Nisio M, Mulder FI, van Es N, et al
    Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
    Thromb Haemost. 2018;118:1439-1449.
    PubMed     Text format     Abstract available


  11. JIMENEZ D, Bikdeli B
    Scores to Identify Occult Cancer in Venous Thromboembolism: Do They Work?
    Thromb Haemost. 2018;118:1343-1344.
    PubMed     Text format    


    July 2018
  12. PETTERSON TM, Smith CY, Emerson JA, Bailey KR, et al
    Venous Thromboembolism (VTE) Incidence and VTE-Associated Survival among Olmsted County Residents of Local Nursing Homes.
    Thromb Haemost. 2018;118:1316-1328.
    PubMed     Text format     Abstract available


    June 2018
  13. KRAAIJPOEL N, van Es N, Raskob GE, Buller HR, et al
    Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study.
    Thromb Haemost. 2018 Jun 4. doi: 10.1055/s-0038-1649523.
    PubMed     Text format     Abstract available


    April 2018
  14. FRERE C, Trujillo-Santos J, Font C, Samperiz A, et al
    Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry.
    Thromb Haemost. 2018 Apr 21. doi: 10.1055/s-0038-1642009.
    PubMed     Text format    


  15. BAUERSACHS R, Lee AYY, Kamphuisen PW, Meyer G, et al
    Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
    Thromb Haemost. 2018 Apr 4. doi: 10.1055/s-0038-1641150.
    PubMed     Text format     Abstract available


  16. BOURGUIGNON T, Bernard A, Fauchier L
    Risk of Thromboembolic Events without Oral Anticoagulation at 90 Days after Surgical Aortic Valve Replacement with a Bioprosthesis.
    Thromb Haemost. 2018 Apr 4. doi: 10.1055/s-0038-1641167.
    PubMed     Text format    


  17. HUGON-RODIN J, Horellou MH, Conard J, Gompel A, et al
    Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism.
    Thromb Haemost. 2018 Apr 3. doi: 10.1055/s-0038-1641152.
    PubMed     Text format     Abstract available


  18. GOLDMAN S, Fraczek P, Szklanny K, Papuga-Szela E, et al
    Altered Plasma Clot Properties and Trauma-Related Venous Thromboembolism despite Thromboprophylaxis.
    Thromb Haemost. 2018;118:654-663.
    PubMed     Text format     Abstract available


    March 2018
  19. KHORANA AA, Weitz JI
    Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
    Thromb Haemost. 2018 Mar 22. doi: 10.1160/TH17-09-0681.
    PubMed     Text format     Abstract available


  20. CAMM AJ
    The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.
    Thromb Haemost. 2018 Mar 22. doi: 10.1055/s-0038-1632387.
    PubMed     Text format     Abstract available


  21. BARBERO E, Bikdeli B, Chiluiza D, Barrios D, et al
    Performance of Early Prognostic Assessment Independently Predicts the Outcomes in Patients with Acute Pulmonary Embolism.
    Thromb Haemost. 2018 Mar 19. doi: 10.1055/s-0038-1637746.
    PubMed     Text format    


  22. LEHNERT P, Lange T, Moller CH, Olsen PS, et al
    Acute Pulmonary Embolism in a National Danish Cohort: Increasing Incidence and Decreasing Mortality.
    Thromb Haemost. 2018;118:539-546.
    PubMed     Text format     Abstract available


    February 2018
  23. LUTSEY PL, Horvath KJ, Fullam L, Moll S, et al
    Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients.
    Thromb Haemost. 2018 Feb 15. doi: 10.1055/s-0038-1625985.
    PubMed     Text format     Abstract available


  24. MARTOS L, Ramon LA, Oto J, Fernandez-Pardo A, et al
    alpha2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:alpha2M Levels Are Associated with Venous Thromboembolism.
    Thromb Haemost. 2018 Feb 15. doi: 10.1055/s-0038-1629902.
    PubMed     Text format     Abstract available


  25. VAN DER POL LM, van der Hulle T, Mairuhu ATA, Huisman MV, et al
    Combination of Pulmonary Embolism Rule-out Criteria and YEARS Algorithm in a European Cohort of Patients with Suspected Pulmonary Embolism.
    Thromb Haemost. 2018 Feb 1. doi: 10.1055/s-0038-1623535.
    PubMed     Text format     Abstract available


  26. SPRONK HMH, Padro T, Siland JE, Prochaska JH, et al
    Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.
    Thromb Haemost. 2018;118:229-250.
    PubMed     Text format     Abstract available


    January 2018
  27. BIKDELI B, Jimenez D, Hawkins M, Ortiz S, et al
    Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE).
    Thromb Haemost. 2018;118:214-224.
    PubMed     Text format     Abstract available


  28. BLONDON M, Spirk D, Kucher N, Aujesky D, et al
    Comparative Performance of Clinical Risk Assessment Models for Hospital-Acquired Venous Thromboembolism in Medical Patients.
    Thromb Haemost. 2018;118:82-89.
    PubMed     Text format     Abstract available


    December 2017
  29. KLOK FA, Ageno W, Barco S, Binder H, et al
    Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.
    Thromb Haemost. 2017;117:2425-2434.
    PubMed     Text format    


  30. MEDINA A, Raskob G, Ageno W, Cohen AT, et al
    Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
    Thromb Haemost. 2017;117:2406-2414.
    PubMed     Text format    


  31. RAUZI F, Smyth E, Emerson M
    Refinement of Mouse Protocols for the Study of Platelet Thromboembolic Responses In Vivo.
    Thromb Haemost. 2017;117:2283-2290.
    PubMed     Text format    


  32. BYKOV K, Bohn RL, Ewenstein BM, Seeger JD, et al
    Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.
    Thromb Haemost. 2017;117:2267-2273.
    PubMed     Text format    


  33. LEE LH, Gallus A, Jindal R, Wang C, et al
    Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review.
    Thromb Haemost. 2017;117:2243-2260.
    PubMed     Text format    


    November 2017
  34. HALTON JML, Picard AC, Harper R, Huang F, et al
    Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
    Thromb Haemost. 2017;117:2168-2175.
    PubMed     Text format     Abstract available


  35. DEN EXTER PL, Hooijer J, van der Hulle T, van Oosten JP, et al
    Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice.
    Thromb Haemost. 2017;117:2163-2167.
    PubMed     Text format     Abstract available


  36. KHORANA AA, Vadhan-Raj S, Kuderer NM, Wun T, et al
    Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial.
    Thromb Haemost. 2017;117:2135-2145.
    PubMed     Text format     Abstract available


  37. GOLDHABER SZ, Schulman S, Eriksson H, Feuring M, et al
    Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.
    Thromb Haemost. 2017;117:2045-2052.
    PubMed     Text format     Abstract available


    October 2017
  38. BASS AR, Fields KG, Goto R, Turissini G, et al
    Clinical Decision Rules for Pulmonary Embolism in Hospitalized Patients: A Systematic Literature Review and Meta-analysis.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  39. VAN OMMEN CH, Klaassen ILM, van Els AL, van de Wetering MD, et al
    Increasing Incidence and Recurrence Rate of Venous Thromboembolism in Paediatric Oncology Patients in One Single Centre Over 25 Years.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  40. GOLDHABER SZ, Schulman S, Eriksson H, Feuring M, et al
    Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Pooled analysis of RE-COVER and RE-COVER II.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  41. DEN EXTER PL, Hooijer J, van der Hulle T, van Oosten JP, et al
    Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


    September 2017
  42. KHORANA A, Vadhan-Raj S, Kuderer NM, Wun T, et al
    Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  43. SCHULMAN S
    Accumulating data on rivaroxaban for venous thromboembolism in clinical practice.
    Thromb Haemost. 2017;117.
    PubMed     Text format    


    August 2017
  44. SEILER E, Limacher A, Mean M, Beer HJ, et al
    Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  45. MCBANE RD, Loprinzi CL, Ashrani A, Perez-Botero J, et al
    Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  46. BLEKER SM, Brekelmans MPA, Eerenberg ES, Cohen AT, et al
    Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  47. ANETSBERGER A, Blobner M, Haller B, Schmid S, et al
    Immature platelets as a novel biomarker for adverse cardiovascular events in patients after non-cardiac surgery.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  48. TAKACH LAPNER S, Julian JA, Linkins LA, Bates S, et al
    Comparison of clinical probability-adjusted D-dimer and age-adjusted D-dimer interpretation to exclude venous thromboembolism.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  49. JANION-SADOWSKA A, Natorska J, Siudut J, Zabczyk M, et al
    Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


    June 2017
  50. COLEMAN CI, Coleman C, Bunz TJ, Turpie AGG, et al
    Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  51. SCHULMAN S, Ageno W, Konstantinides SV
    Venous thromboembolism: Past, present and future.
    Thromb Haemost. 2017;117:1219-1229.
    PubMed     Text format     Abstract available


  52. VAN DER HULLE T, van Es N, den Exter P, van Es J, et al
    Is a normal computed tomography pulmonary angiography safe to rule out acute pulmonary embolism in patients with a likely clinical probability? A patient-level meta-analysis.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


    May 2017
  53. CHUNG WS, Lin CL
    Increased risks of venous thromboembolism in patients with psoriasis. A Nationwide Cohort Study.
    Thromb Haemost. 2017 May 24. doi: 10.1160/TH17-01-0039.
    PubMed     Text format     Abstract available


    April 2017
  54. SANTI RM, Ceccarelli M, Bernocco E, Monagheddu C, et al
    Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL).
    Thromb Haemost. 2017 Apr 27. doi: 10.1160/TH16-11-0895.
    PubMed     Text format     Abstract available


  55. SCHULMAN S, Singer D, Ageno W, Casella IB, et al
    NOACs for treatment of venous thromboembolism in clinical practice.
    Thromb Haemost. 2017 Apr 20. doi: 10.1160/TH17-01-0065.
    PubMed     Text format     Abstract available


  56. COHEN AT, Gitt AK, Bauersachs R, Fronk EM, et al
    The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.
    Thromb Haemost. 2017 Apr 13. doi: 10.1160/TH16-10-0793.
    PubMed     Text format     Abstract available


    March 2017
  57. RAJPURKAR M, Biss T, Amankwah E, Martinez D, et al
    Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics. A systematic review.
    Thromb Haemost. 2017 Mar 23. doi: 10.1160/TH16-07-0529.
    PubMed     Text format     Abstract available


  58. SINDET-PEDERSEN C, Langtved Pallisgaard J, Staerk L, Gerds TA, et al
    Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study.
    Thromb Haemost. 2017 Mar 16. doi: 10.1160/TH16-10-0745.
    PubMed     Text format     Abstract available


  59. TAFUR AJ, Caprini JA, Cote L, Trujillo-Santos J, et al
    Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
    Thromb Haemost. 2017 Mar 9. doi: 10.1160/TH16-11-0840.
    PubMed     Text format     Abstract available


  60. KLOK FA, Barco S, Konstantinides SV
    External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism.
    Thromb Haemost. 2017 Mar 9. doi: 10.1160/TH16-10-0810.
    PubMed     Text format     Abstract available


    February 2017

  61. Erratum to Heit et al. "Reasons for the persistent incidence of venous thromboembolism" (Thromb Haemost 2017; 117: 390-400).
    Thromb Haemost. 2017;117:643.
    PubMed     Text format    


  62. DENTALI F, Mumoli N, Prisco D, Fontanella A, et al
    Efficacy and safety of extended thromboprophylaxis for medically ill patients. A meta-analysis of randomised controlled trials.
    Thromb Haemost. 2017;117:606-617.
    PubMed     Text format     Abstract available


  63. DING Q, Yang L, Zhao X, Wu W, et al
    Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation.
    Thromb Haemost. 2017;117:479-490.
    PubMed     Text format     Abstract available


  64. HEIT JA, Armasu SM, McCauley BM, Kullo IJ, et al
    Identification of unique venous thromboembolism-susceptibility variants in African-Americans.
    Thromb Haemost. 2017 Feb 16. doi: 10.1160/TH16-08-0652.
    PubMed     Text format     Abstract available


  65. BREKELMANS MP, Scheres LJ, Bleker SM, Hutten BA, et al
    Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
    Thromb Haemost. 2017 Feb 9. doi: 10.1160/TH16-11-0874.
    PubMed     Text format     Abstract available


  66. STUCK AK, Spirk D, Schaudt J, Kucher N, et al
    Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review.
    Thromb Haemost. 2017 Feb 2. doi: 10.1160/TH16-08-0631.
    PubMed     Text format     Abstract available


  67. BOCHENEK ML, Rosinus NS, Lankeit M, Hobohm L, et al
    From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension.
    Thromb Haemost. 2017 Feb 2. doi: 10.1160/TH16-10-0790.
    PubMed     Text format     Abstract available


    January 2017
  68. CHAI-ADISAKSOPHA C, Linkins LA, ALKindi SY, Cheah M, et al
    Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours.
    Thromb Haemost. 2017 Jan 12. doi: 10.1160/TH16-09-0680.
    PubMed     Text format     Abstract available


  69. ZHAO B, Zhang Y, Huang Y, Yu J, et al
    A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection.
    Thromb Haemost. 2017;117:44-56.
    PubMed     Text format     Abstract available


    December 2016
  70. HEIT JA, Ashrani A, Crusan DJ, McBane RD, et al
    Reasons for the persistent incidence of venous thromboembolism.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


    November 2016
  71. CHATTERJEE S, Weinberg I, Yeh RW, Chakraborty A, et al
    Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


  72. AY C, Pabinger I, Cohen AT
    Cancer-associated venous thromboembolism: Burden, mechanisms, and management.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


  73. AGENO W, Casella I, Han CK, Raskob GE, et al
    RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


    October 2016
  74. TRUJILLO-SANTOS J, Di Micco P, Dentali F, Douketis J, et al
    Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


  75. RIEDL J, Kaider A, Marosi C, Prager GW, et al
    Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available


  76. AMBROSINO P, Tarantino L, Di Minno G, Paternoster M, et al
    The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available



  77. Venous thromboembolism: A Call for risk assessment in all hospitalised patients.
    Thromb Haemost. 2016;116:777-779.
    PubMed     Text format    


  78. COHEN AT, Katholing A, Rietbrock S, Bamber L, et al
    Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available


    September 2016

  79. Erratum to Barco et al. "Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial" (Thromb Haemost 2016; 116: 191-197).
    Thromb Haemost. 2016;116:775.
    PubMed     Text format     Abstract available


  80. WEITZ JI, Haas S, Ageno W, Angchaisuksiri P, et al
    Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  81. CAPPATO R, Welsh R
    Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Venous Thrombosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: